Up to
90%
of recurrent nasal polyps have predominantly eosinophilic inflammation
Nucala
Daily
Challenge
A new question each day. Keep answering until you find the right one, then see the evidence behind it.
3 days · 3 questions
Daily
Day
1
Day 1 challenge
Eosinophils and nasal polyp recurrence
One question. Keep trying until you find the right answer.
Ready for the next player
Day 1 / Question
Patient profile
Tap the answer you think is right.
Day 1 / The evidence
Answer C · 3× higherEosinophilic inflammation can drive nasal polyp recurrence
After surgery, nasal polyp recurrence was
3×
higher with high tissue eosinophil density1
Nucala significantly reduced risk of sinus surgery compared with placebo1
57%
reduction in the risk of sinus surgery with mepolizumab
Better result with more recent nasal polyp surgery2
Time since last sinus surgery before mepolizumab
< 3 years
72%
HR 0.28
95% CI 0.09, 0.84
≥ 3 years
50%
HR 0.50
95% CI 0.26, 0.98
Reduction in need for repeat nasal polyp surgery at week 52 with mepolizumab vs placebo
Nucala reduced the rate of asthma exacerbations by 80% versus placebo in patients with severe eosinophilic asthma and CRSwNP
+
Severe eosinophilic asthma + CRSwNP
80%
Reduction in asthma exacerbations
RR 0.20 (95% CI 0.11, 0.35)
Rate of asthma exacerbations, relative to placebo
MENSA/MUSCA post hoc meta-analysis: Nucala 100 mg SC or placebo1